Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)

This study has been completed.
Sponsor:
Information provided by:
Genentech, Inc.
ClinicalTrials.gov Identifier:
NCT00486018
First received: June 11, 2007
Last updated: April 25, 2011
Last verified: April 2011

June 11, 2007
April 25, 2011
July 2007
May 2009   (final data collection date for primary outcome measure)
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
BCVA score in the study eye was based on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.
Mean change from baseline in BCVA score at 6 months
Complete list of historical versions of study NCT00486018 on ClinicalTrials.gov Archive Site
  • Percentage of Participants Who Gained ≥ 15 Letters in BCVA Score at Month 6 Compared With Baseline [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
    BCVA score based on the ETDRS visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters.
  • Percentage of Participants Who Lost < 15 Letters in BCVA Score at Month 6 Compared With Baseline [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
    BCVA score based on the ETDRS visual acuity charts (number of correct letters) and assessed at a starting distance of 4 meters. The percentage of subjects who lost <15 letters will be greater than the percentage of subjects who "gained >=15 letters" as "losing <15 letters" includes both those who gained >=15 letters and those who were "stable" (i.e. lost between 1 and 14 letters, had no change, or gained between 1 and 14 letters).
  • Percentage of Participants With a Central Foveal Thickness of ≤ 250 μm at Month 6 [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    A central reading center assessed all optical coherence tomography (OCT) images. Central foveal thickness was defined as the center point thickness.
  • Mean Absolute Change From Baseline in Central Foveal Thickness at Month 6 [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
    A central reading center assessed all OCT images. Central foveal thickness was defined as the center point thickness.
  • Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) Near Activities Subscale Score at Month 6 [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
    The NEI VFQ-25 (v. 2000; Interviewer Format) consisted of the base set of 25 questions, plus the optional additional questions (where questions A3, A4, and A5 pertained to the Near Activities Subscale). Scores ranged from 0 to 100; a higher score represented better functioning.
  • Mean Change From Baseline in the NEI VFQ-25 Distance Activities Subscale Score at Month 6 [ Time Frame: Baseline and 6 months ] [ Designated as safety issue: No ]
    The NEI VFQ-25 (v. 2000; Interviewer Format) consisted of the base set of 25 questions, plus the optional additional questions (where questions A6, A7, and A8 pertained to the Distance Activities Subscale). Scores ranged from 0 to 100; a higher score represented better functioning.
  • Proportion of subjects who gain at least 15 letters in BCVA score at 6 months compared with baseline
  • Proportion of subjects who lose fewer than 15 letters in BCVA score at 6 months compared with baseline
  • Mean change from baseline in BCVA score over time up to 6 months
  • Proportion of subjects with a central foveal thickness of ≤ 250 um, assessed by OCT, at 6 months
  • Mean absolute change from baseline in central foveal thickness, assessed by OCT, over time up to 6 months
  • Mean change from baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) near activities subscale over time up to 6 months
  • Mean change from baseline in the NEI VFQ-25 distance activities subscale over time up to 6 months
Not Provided
Not Provided
 
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)
A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion

This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to branch retinal vein occlusion (BRVO); 397 patients with BRVO were enrolled at 93 investigational sites in the United States. The study included a treatment period (6 months) and an observation period (6 months).

Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
  • Macular Edema
  • Retinal Vein Occlusion
  • Drug: Ranibizumab injection 0.3 mg
    Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
    Other Name: Lucentis
  • Drug: Ranibizumab injection 0.5 mg
    Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
    Other Name: Lucentis
  • Drug: Sham injection
    Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
  • Sham Comparator: Sham injection
    Intervention: Drug: Sham injection
  • Experimental: Ranibizumab injection 0.3 mg
    Intervention: Drug: Ranibizumab injection 0.3 mg
  • Experimental: Ranibizumab injection 0.5 mg
    Intervention: Drug: Ranibizumab injection 0.5 mg

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
397
November 2009
May 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Willingness to provide signed Informed Consent Form
  • Age ≥ 18 years
  • For sexually active women of childbearing potential, use of an appropriate form of contraception (or abstinence) for the duration of the study
  • Ability and willingness to return for all scheduled visits and assessments

Ocular Inclusion Criterion (Study Eye):

  • Foveal center-involved macular edema secondary to BRVO
  • BCVA using ETDRS charts of 20/40 to 20/400 (Snellen equivalent)
  • Mean central subfield thickness ≥ 250 μm on two optical coherence tomography (OCT) measurements (at screening [confirmed by the central reading center] and Day 0 [confirmed by the evaluating physician])
  • Media clarity, pupillary dilation, and participant cooperation sufficient to obtain adequate fundus photographs

Exclusion Criteria:

  • History of cerebral vascular accident or myocardial infarction within 3 months prior to Day 0
  • History of any anti-vascular endothelial growth factor (VEGF) treatment in fellow eye within 3 months prior to Day 0
  • History of any systemic anti-VEGF or pro-VEGF treatment within 6 months prior to Day 0
  • History of allergy to fluorescein
  • History of allergy to ranibizumab injection or related molecule
  • Relevant systemic disease that may be associated with increased systemic VEGF levels (namely, all active malignancies); history of successfully treated malignancies is not an exclusion criterion
  • Uncontrolled blood pressure
  • Pregnancy or lactation
  • Any condition that, in the opinion of the investigator, would preclude participation in the study (e.g., chronic alcoholism or drug abuse, personality disorder or use of major tranquilizers, indicated difficulty in long-term follow-up, and likelihood of survival of less than 1 year)
  • Participation in an investigational trial within 30 days prior to Day 0 that involved treatment with any drug (excluding vitamins and minerals) or device that has not received regulatory approval at time of study entry

Ocular Exclusion Criteria (Study Eye):

  • Prior episode of retinal vein occlusion (RVO)
  • Brisk afferent pupillary defect
  • History of radial optic neurotomy or sheathotomy
  • History or presence of age-related macular degeneration (AMD; dry or wet form)
  • History of any anti-VEGF treatment in the study eye within 3 months prior to Day 0
  • History of laser photocoagulation for macular edema within 4 months prior to Day 0
  • History of panretinal scatter photocoagulation or sector laser photocoagulation within 3 months prior to randomization or anticipated within the next 4 months following randomization
  • History of intraocular corticosteroid use within 3 months prior to Day 0
  • History of pars plana vitrectomy
  • History of intraocular surgery (including cataract extraction, scleral buckle, etc.) within 2 months prior to Day 0 or anticipated within the next 7 months following Day 0
  • History of yttrium-aluminum-garnet capsulotomy performed within 2 months prior to Day 0
  • Previous filtration surgery in the study eye
  • History of herpetic ocular infection
  • History of ocular toxoplasmosis
  • History of rhegmatogenous retinal detachment
  • History of idiopathic central serous chorioretinopathy
  • Evidence upon examination of vitreoretinal interface disease (e.g., vitreomacular traction, epiretinal membrane), either on clinical examination or OCT, thought to be contributing to macular edema
  • An eye that, in the investigator's opinion, would not benefit from resolution of macular edema, such as eyes with foveal atrophy, dense pigmentary changes, or dense subfoveal hard exudates
  • Presence of an ocular condition that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the study (e.g., uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass syndrome, or prior macula-off rhegmatogenous retinal detachment)
  • Visually significant hemorrhage obscuring the fovea and felt to be a major contributor to reduced visual acuity
  • Presence of a substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more (i.e., a 20/40 cataract)
  • Aphakia
  • Relevant ocular disease that may be associated with increased intraocular VEGF levels (namely, uveitis, neovascular glaucoma, neovascular AMD, diabetic retinopathy, diabetic maculopathy, or ocular ischemic syndrome)
  • Improvement of > 10 letters on best corrected visual acuity (BCVA) between screening and Day 0
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00486018
FVF4165g
Not Provided
Disclosures Group, Genentech, Inc.
Genentech, Inc.
Not Provided
Study Director: Roman Rubio, M.D. Genentech, Inc.
Genentech, Inc.
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP